nVerses Capital LLC acquired a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 2,600 shares of the biopharmaceutical company’s stock, valued at approximately $102,000.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. bought a new stake in Xenon Pharmaceuticals during the 4th quarter worth approximately $91,000. Quarry LP grew its holdings in shares of Xenon Pharmaceuticals by 207.7% in the second quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock valued at $156,000 after acquiring an additional 2,700 shares in the last quarter. EntryPoint Capital LLC bought a new position in shares of Xenon Pharmaceuticals in the first quarter valued at approximately $195,000. ProShare Advisors LLC grew its holdings in shares of Xenon Pharmaceuticals by 12.0% in the first quarter. ProShare Advisors LLC now owns 5,286 shares of the biopharmaceutical company’s stock valued at $228,000 after acquiring an additional 565 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. grew its holdings in shares of Xenon Pharmaceuticals by 21.4% in the first quarter. Oppenheimer Asset Management Inc. now owns 5,374 shares of the biopharmaceutical company’s stock valued at $231,000 after acquiring an additional 946 shares in the last quarter. 95.45% of the stock is owned by institutional investors.
Xenon Pharmaceuticals Price Performance
NASDAQ:XENE opened at $44.86 on Monday. The company has a market cap of $3.39 billion, a P/E ratio of -16.55 and a beta of 1.25. The stock’s fifty day moving average price is $40.00 and its two-hundred day moving average price is $40.16. Xenon Pharmaceuticals Inc. has a 1 year low of $27.99 and a 1 year high of $50.99.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on the company. William Blair raised Xenon Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 target price on shares of Xenon Pharmaceuticals in a report on Friday, August 9th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, September 3rd. Needham & Company LLC reduced their price objective on Xenon Pharmaceuticals from $62.00 to $60.00 and set a “buy” rating for the company in a report on Monday, August 12th. Finally, Raymond James reissued an “outperform” rating and set a $50.00 price objective on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. Eleven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $57.45.
View Our Latest Stock Report on XENE
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Further Reading
- Five stocks we like better than Xenon Pharmaceuticals
- How to invest in marijuana stocks in 7 stepsĀ
- Is Spotify Stock Poised to Soar? Options Traders Think So
- The 3 Best Blue-Chip Stocks to Buy Now
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Most active stocks: Dollar volume vs share volume
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.